DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD

NCT07249112 | Recruiting

• 1 other identifier: DETECTIVE
• Study Type: interventional
• Target: 2,880
• Locations: 1 country
• Sites: 1

Brief Summary

The Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a leading cause of chronic liver disease globally, with a prevalence exceeding 30% in the population. MASLD is strictly associated with insulin resistance and cardiometabolic conditions, and in 20-30% of cases, it can progress to steatohepatitis (MASH), which is characterized by progressive liver damage and inflammation. In patients at higher risk, the disease can lead to the onset of advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). One of the main problems in the clinical management of MASLD is the absence of specific risk biomarkers and the lack of effective treatments, especially for patients with advanced-stage disease. MASLD has a well-documented and enormous genetic component, with studies having identified several common variants associated with this pathology, such as those in the PNPLA3, TM6SF2, and MBOAT7 genes. However, these variants identified so far only explain a small part of MASLD's heritability, suggesting the contribution of rare loss-of-function (LoF) variants as well. Furthermore, scientific evidence indicates that the accumulation of somatic variants, both in hepatocytes and myeloid cells, could also play a key role in MASLD progression. In particular, clonal hematopoiesis of indeterminate potential (CHIP), which is a condition characterized by the presence of hematopoietic clones with somatic mutations often associated with leukemia and cardiovascular diseases, might favor the onset of hepatocellular carcinoma. However, the evidence available to date is still limited and requires further investigation and studies on larger cohorts. The current study therefore aims to deepen this aspect through the analysis of the genetic profile using a Whole-Genome Sequencing (WGS) approach. DNA samples from peripheral blood from patients with advanced MASLD and peripheral blood DNA samples from controls presenting various associated metabolic risk factors will be sequenced. In addition, 80 liver tissue samples from patients with advanced MASLD will also be sequenced to identify specific somatic mutations. The expected results from this study include the identification of new genetic variants associated with MASLD progression, the improvement of risk stratification through the development of polygenic risk scores, and the identification of potential therapeutic targets. This study represents a fundamental step for understanding the biology of MASLD and could have important clinical implications for disease management.

Conditions

Cirrhosis; MASLD

Outcome Measures

Primary Outcomes (1)

• Identifying Genetic Risk for Advanced MASLD

  The study's outcome measures are defined by two distinct, primary endpoints. The first is the Number of Genetic Variants Associated with Advanced MASLD, reported as the total count of genetic variants (germline and/o somatic) exhibiting a statistically significant association with the risk of developing advanced Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), defined as fibrosis ≥ 2 and/or hepatocellular carcinoma. The unit of measure for this outcome is Count (Number of variants). The second measure is the Odds Ratio (OR) for Association Between Germline Variants and Advanced MASLD, calculated by comparing the presence of specific germline variants in cases versus controls to determine the strength of their association with advanced MASLD.

  11 months

Secondary Outcomes (1)

• Mechanisms, Risk Stratification, and Therapy

  11 months

Study Arms (1)

Advanced MASLD Patients and Metabolic Controls

EXPERIMENTAL

This study aims to identify inherited genetic variants and somatic mutations associated with the progression of advanced Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD.The research utilizes two distinct and extensively characterized cohorts for Whole-Genome Sequencing WGS analysis: * MASLD Cohort: Consists of 800 patients whose peripheral blood will undergo WGS at 20x coverage. * Metabolic Controls} Cohort: Comprises 2000 individuals matched for sex and metabolic risk factors who meet at least two criteria for metabolic syndrome but are free of MASLD. Their peripheral blood DNA will also be sequenced.

Other: genetic and somatic variants involved in its progression toward advanced fibrosis and hepatocellular carcinoma

Interventions

genetic and somatic variants involved in its progression toward advanced fibrosis and hepatocellular carcinoma OTHER

The focusing is the attention on the genetic and somatic variants involved in its progression toward advanced fibrosis and hepatocellular carcinoma. Through Whole-Genome Sequencing WGS of 800 patients with advanced MASLD, 80 liver tissue samples, and 2000 controls, the study aims to: * Identify rare and structural genetic variants associated with the disease * Analyze the role of clonal hematopoiesis of indeterminate potential CHIP in MASLD progression. * Develop polygenic risk scores to improve risk stratification.

Advanced MASLD Patients and Metabolic Controls

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with advanced MASLD defined as liver fibrosis ≥2 and/or the development of HCC (Hepatocellular Carcinoma);
• Patients enrolled in the context of the SERENA study and, where applicable, also in the context of the REASON study;
• Liver biopsy for suspected Non-Alcoholic Steatohepatitis (NASH) at the time of diagnosis;
• Cholecystectomies;
• Age \[40-70 years\];
• Patients who have signed the informed consent form.
• Blood donors participating in the Liver Bible study aged between 40 and 70 years who are overweight or obese and have at least two of the following risk factors:
• Impaired fasting glucose or Diabetes Mellitus
• Dyslipidemia
• Arterial hypertension.

You may not qualify if:

• Positivity for chronic viral hepatitis (HCV-RNA and/or HBsAg);
• Positivity for other liver diseases such as autoimmune and viral hepatitis (Hepatitis B and C), hereditary hemochromatosis, alpha-1-antitrypsin deficiency, or Wilson's disease.
• Subjects with chronic degenerative diseases will be excluded, with the exception of well-controlled hypertension and Type 2 Diabetes Mellitus that does not require pharmacological therapy (as is already standard practice for blood donation eligibility). Also excluded are donors aged \> 65 and \< 40 years.

Sponsors & Collaborators

• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: lead

Study Sites (1)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica

Milan, Milano, 20122, Italy

RECRUITING

MeSH Terms

Conditions

Fibrosis

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Luca Vittorio Carlo Valenti, Doctor

CONTACT

02 5503 6595; luca.valenti@policlinico.mi.it

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigation, Medical Doctor

Study Record Dates

• First Submitted: November 17, 2025
• First Posted: November 25, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): July 31, 2026
• Study Completion (Estimated): August 31, 2026
• Last Updated: November 25, 2025

Record last verified: 2025-11

Locations

IT (1)